share_log

雲頂新耀-B：有關須予披露交易的更新資料-有關COVID-19疫苗及若干授權產品的製造、開發及商業化的(1)合作及授權許可協議；及(2)股份發行協議

EVEREST MED-B: UPDATE IN RELATION TO DISCLOSEABLE TRANSACTION - (1) COLLABORATION AND LICENSE AGREEMENT; AND (2) SHARE ISSUANCE AGREEMENT IN RESPECT OF THE MANUFACTURE, DEVELOPMENT AND COMMERCIALIZATION OF COVID-19 VACCINES AND CERTAIN LICENSED PRODUCTS

香港交易所 ·  Feb 18 18:50
Summary by Moomoo AI
雲頂新耀有限公司（「本公司」）宣布，與Providence就COVID-19疫苗及其他授權產品的合作及授權許可協議和股份發行協議達成終止協議。該終止協議於2024年2月16日生效，結束雙方所有義務及責任。本公司將支付Providence一次性4百萬美元及潛在監管里程碑付款，並就雙方銷售合作產品支付特許權費用。此外，雙方同意共享某些知識產權，並允許本公司使用Providence提供的mRNA平台開發產品。董事會認為終止協議不會對公司業務及財務造成重大不利影響，並將提供更大靈活性以符合公司策略。
雲頂新耀有限公司（「本公司」）宣布，與Providence就COVID-19疫苗及其他授權產品的合作及授權許可協議和股份發行協議達成終止協議。該終止協議於2024年2月16日生效，結束雙方所有義務及責任。本公司將支付Providence一次性4百萬美元及潛在監管里程碑付款，並就雙方銷售合作產品支付特許權費用。此外，雙方同意共享某些知識產權，並允許本公司使用Providence提供的mRNA平台開發產品。董事會認為終止協議不會對公司業務及財務造成重大不利影響，並將提供更大靈活性以符合公司策略。
Genting Xinyu Limited (the “Company”) announces that it has reached a termination agreement with Providence for the cooperation and authorization of the license agreement and share issue agreement with Providence for COVID-19 vaccines and other licensed products. The Termination Agreement shall enter into force on 16 February 2024, terminating all obligations and responsibilities of the Parties. The Company will pay Providence a one-time payment of $4 million and a potential regulatory milestone, and will pay royalty fees for the sale of the partnership product. In addition, the parties agree to share certain intellectual property rights and allow us to develop products using the mRNA platform provided by Providence. The Board considers that the termination agreement will not have a material adverse effect on the Company's business and finances and will provide greater flexibility to comply with the Company's strategy.
Genting Xinyu Limited (the “Company”) announces that it has reached a termination agreement with Providence for the cooperation and authorization of the license agreement and share issue agreement with Providence for COVID-19 vaccines and other licensed products. The Termination Agreement shall enter into force on 16 February 2024, terminating all obligations and responsibilities of the Parties. The Company will pay Providence a one-time payment of $4 million and a potential regulatory milestone, and will pay royalty fees for the sale of the partnership product. In addition, the parties agree to share certain intellectual property rights and allow us to develop products using the mRNA platform provided by Providence. The Board considers that the termination agreement will not have a material adverse effect on the Company's business and finances and will provide greater flexibility to comply with the Company's strategy.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more